伊马替尼(哌啶)-N,N-二氧化物 | 571186-93-1

• 物质功能分类: 原料药 - 抗肿瘤药 - 替尼类抗肿瘤药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 伊马替尼(哌啶)-N,N-二氧化物
• 中文别名: 伊马替尼进口标准杂质B；伊马替尼(哌啶)-N，N-二氧化物
• 英文名称: 4-(4-methyl-1,4-dioxypiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]benzamide
• 英文别名: 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazine-1,4-dioxide；Imatinib (Piperidine)-N,N-dioxide；4-[(4-methyl-1,4-dioxidopiperazine-1,4-diium-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
• CAS: 571186-93-1
• 化学式: C₂₉H₃₁N₇O₃
• 分子量: 525.61
• InChiKey: MFKGVMIUOYNDCV-UHFFFAOYSA-N

物化性质

• 熔点：
  209-211°C
• 溶解度：
  可溶于乙酸乙酯（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为产物：
  描述：

  伊马替尼 在 双氧水 作用下， 反应 12.0h， 生成 伊马替尼(哌啶)-N,N-二氧化物
  参考文献：
  名称：

  Degradation of biologically active substances by vapor-phase hydrogen peroxide

  摘要：

  我们已经考察了气相过氧化氢（VPHP）对21种结构不同的药物降解的潜在能力。结果显示，VPHP可用于降解药物，但它并非普遍适用于所有被测试的药物上。结构分析揭示了化合物分子结构与其对VPHP的敏感性之间的显著相关性。三甲胺基团似乎是触发中心，尽管一个物质整体的敏感性也取决于其他因素。一些被测试的物质经历了显著的结构变化，暗示其生物活性可能有所下降。就我们所知，这是首批关于VPHP应用于危险化学品净化的报告之一。

  DOI：

  10.1007/s11164-012-0987-x

文献信息

• Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin
  作者：Paul W. Manley

  DOI：10.2533/chimia.2019.561

  日期：——

  The efficacy and side-effects of drugs do not just reflect the biochemical and pharmacodynamic properties of the parent compound, but often comprise of cooperative effects between the properties of the parent and active metabolites. Metabolites of imatinib, nilotinib and midostaurin have been synthesised and evaluated in assays to compare their properties as protein kinase inhibitors with the parent drugs. The N-desmethyl-metabolite of imatinib is substantially less active than imatinib as a BCR-ABL1 kinase inhibitor, thus providing an explanation as to why patients producing high levels of this metabolite show a relatively low response rate in chronic myeloid leukaemia (CML) treatment. The hydroxymethylphenyl and N-oxide metabolites of imatinib and nilotinib are only weakly active as BCR-ABL1 inhibitors and are unlikely to play a role in the efficacy of either drug in CML. The 3-(R)-HO-metabolite of midostaurin shows appreciable accumulation following chronic drug administration and, in addition to mutant forms of FLT3, potently inhibits the PDPK1 and VEGFR2 kinases (IC50 values

  药物的功效和副作用不仅仅反映了母化合物的生化和药效特性，而且通常包括母化合物和活性代谢物之间的协同效应。已经合成和评估了伊马替尼、尼洛替尼和米多斯他林的代谢物，以比较它们作为蛋白激酶抑制剂的特性与母药的区别。伊马替尼的N-去甲基代谢物作为BCR-ABL1激酶抑制剂的活性明显低于伊马替尼，这解释了为什么产生高水平该代谢物的患者在慢性髓细胞白血病（CML）治疗中显示相对较低的反应率。伊马替尼和尼洛替尼的羟甲基苯和N-氧代谢物作为BCR-ABL1抑制剂的活性很弱，不太可能在CML中发挥作用。米多斯他林的3-(R)-HO-代谢物在长期用药后显示出明显的积累，并且除了FLT3的突变形式外，还强力抑制PDPK1和VEGFR2激酶（IC50值

• N-oxyde of n-phenyl-2-pyrimidine-amine derivatives
  申请人：Bornsen Olaf Klaus

  公开号：US20050209452A1

  公开（公告）日：2005-09-22

  The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

  本发明涉及N-苯基-2-嘧啶胺衍生物，其中至少一个氮原子携带一个氧原子以形成相应的N-氧化物，以及制备这些化合物的过程，包括这些化合物的药物组成物和在制备温血动物，包括人类的治疗性药物组成物中的用途。
• N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
  申请人：BORNSEN Klaus Olaf

  公开号：US20090239879A1

  公开（公告）日：2009-09-24

  The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

  该发明涉及N-苯基-2-嘧啶胺衍生物，其中至少有一个氮原子携带氧原子以形成相应的N-氧化物，以及其制备过程、包含这些化合物的制药组合物以及在制备治疗温血动物，包括人类的制药组合物时的使用。
• N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives
  申请人：Börnsen Klaus Olaf

  公开号：US20110294820A1

  公开（公告）日：2011-12-01

  The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

  该发明涉及N-苯基-2-嘧啶胺衍生物，其中至少一个氮原子携带氧原子以形成相应的N-氧化物，以及其制备方法、包含这些化合物的药物组合物和将其用于制备治疗温血动物，包括人类的药物组合物的用途。
• N-oxides of N-phenyl-2-pyrimidine-amine derivatives
  申请人：Novartis AG

  公开号：US07557105B2

  公开（公告）日：2009-07-07

  The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

  本发明涉及N-苯基-2-嘧啶胺衍生物，其中至少一个氮原子携带一个氧原子以形成相应的N-氧化物，以及其制备过程，包括这些化合物的制药组合物，以及它们在制备治疗温血动物，包括人类的药物组合物中的用途。